此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Comparison of the Effects of Kinesio Taping and Compression Bandaging on Edema, Range of Motion, Upper Extremity Function, and Grip Strength in Patients With Breast Cancer-Related Lymphedema

2026年11月10日 更新者:Halic University

This randomized crossover clinical trial aims to compare the effects of Kinesio Taping and compression bandaging on upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength in patients with breast cancer-related lymphedema.

A total of 44 participants will receive both treatment approaches in different sequences. Each intervention period will last 4 weeks, with a 2-week washout period between treatments. Manual lymphatic drainage will be applied three times per week during the intervention periods. Assessments will be performed at baseline, week 4, and week 10.

研究概览

详细说明

This randomized crossover clinical trial was designed to compare the effects of Kinesio Taping and compression bandaging on upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength in patients with breast cancer-related lymphedema.

A total of 44 participants will be randomly allocated to one of two treatment sequences. In the first 4-week treatment period, one group will receive Kinesio Taping combined with manual lymphatic drainage, while the other group will receive compression bandaging combined with manual lymphatic drainage. Manual lymphatic drainage will be administered three times per week during the intervention periods.

After completion of the first 4-week treatment period, a 2-week washout period will be implemented. Following the washout period, participants will cross over to the alternative intervention for an additional 4 weeks. Participants who initially received Kinesio Taping will subsequently receive compression bandaging, whereas participants who initially received compression bandaging will subsequently receive Kinesio Taping.

Clinical assessments will be performed at baseline, at the end of the first treatment period (week 4), and at the end of the second treatment period (week 10). Upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength will be evaluated at these time points.

The crossover design allows all participants to receive both therapeutic interventions and enables within-participant comparison of the effects of Kinesio Taping and compression bandaging. The 2-week washout period is included to reduce potential carryover effects from the first treatment period before initiation of the second intervention.

研究类型

介入性

注册 (估计的)

44

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Bakırköy
      • Istanbul、Bakırköy、土耳其(türkiye)、34149
        • Istanbul University Cerrahpaşa Faculty of Medicine Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Diagnosis of lymphedema following breast cancer treatment (confirmed by clinical evaluation or objective measurements).
  • Age between 18 and 75 years (adult participants will be included).
  • Willingness to participate voluntarily in the study and provision of written informed consent.
  • Unilateral lymphedema (to ensure standardization of assessments).
  • Lymphedema in the chronic stage (present for more than 3 months).
  • A stable condition in terms of lymphedema treatment (no other lymphedema treatment received within the last month).
  • Sufficient functional capacity to complete physical assessments and measurements (movement limitations should not be at a level that prevents evaluation).

Exclusion Criteria:

  • History of advanced-stage cancer or active metastatic disease.
  • Presence of severe cardiovascular or respiratory disease (e.g., heart failure, chronic obstructive pulmonary disease).
  • History of diabetic neuropathy or peripheral vascular disease (may affect lymphedema management due to circulatory impairment).
  • Presence of severe skin reactions or dermatological conditions (that compromise skin integrity and prevent tape application).
  • Pregnancy or breastfeeding.
  • History of allergic reactions to kinesio tape or compression bandages.
  • History of lymphatic drainage surgery or other surgical intervention within the past 6 months.
  • Diagnosis of bilateral lymphedema (only unilateral cases will be included to standardize the assessment process).
  • Inability to actively participate in the study due to mental or cognitive impairment.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Kinesiotaping Group

Patients with lymphedema who will receive kinesio taping treatment first, followed by compression bandaging.

MLD will accompany both groups throughout the intervention periods. MLD sessions will be administered by a trained physiotherapist three times per week for a total duration of 4 weeks in each treatment period.

Kinesio taping: This technique will be applied to the edematous extremity in accordance with lymphatic drainage directions, three times per week. The tapes will remain in place for 2-3 days at each application.

Compression bandaging: Multi-layer, short-stretch compression bandages will be reapplied after each MLD session (three times per week).

Due to the crossover design of the study, the applied interventions will be switched between groups after the initial 4-week treatment period. Prior to the second intervention phase, a 1-week washout period will be implemented to minimize potential carryover effects from the previous treatment. No treatment will be administered during this washout period.

实验性的:Compression Bandaging

Patients with lymphedema who will receive compression bandaging first, followed by kinesio taping treatment.

MLD will accompany both groups throughout the intervention periods. MLD sessions will be administered by a trained physiotherapist three times per week for a total duration of 4 weeks in each treatment period.

Kinesio taping: This technique will be applied to the edematous extremity in accordance with lymphatic drainage directions, three times per week. The tapes will remain in place for 2-3 days at each application.

Compression bandaging: Multi-layer, short-stretch compression bandages will be reapplied after each MLD session (three times per week).

Due to the crossover design of the study, the applied interventions will be switched between groups after the initial 4-week treatment period. Prior to the second intervention phase, a 1-week washout period will be implemented to minimize potential carryover effects from the previous treatment. No treatment will be administered during this washout period.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Upper Extremity Edema
大体时间:The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Arm circumference measurement was used as an objective indicator of lymphedema severity. Circumferential measurements were obtained using a non-elastic tape measure at standardized anatomical landmarks along the upper extremity. Measurements were taken at fixed intervals (e.g., every 5 cm) starting from the wrist and progressing proximally toward the elbow and upper arm.

Values were recorded in millimeters (mm), with higher circumference values indicating greater edema severity. There is no predefined upper limit for arm circumference; therefore, larger measurements reflect increased fluid accumulation, whereas smaller values indicate reduced edema.

To quantify lymphedema, the difference in circumference between the affected and unaffected extremities was calculated at each measurement point. A greater inter-limb difference represents more severe lymphedema, while a reduction in this difference over time indicates clinical improvement.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Pain Intensity
大体时间:The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

The Visual Analog Scale (VAS) is a 10-centimeter horizontal line used to assess pain intensity. Scores range from 0 to 10, where 0 indicates no pain and 10 indicates worst imaginable pain. Higher scores indicate greater pain severity.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Shoulder Range of Motion
大体时间:The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Joint range of motion (ROM) was assessed to evaluate upper-extremity mobility in individuals with lymphedema. Active ROM measurements were obtained using a standard universal goniometer based on anatomical landmarks. Measurements were recorded in degrees (°) for wrist, elbow, forearm, and shoulder movements.

Higher ROM values indicate greater joint mobility and better functional status, whereas lower values reflect movement limitation. As ROM does not have a single fixed maximum value, results were interpreted relative to anatomical normative values and the contralateral limb.

A reduction of ≥10° compared with the unaffected side was considered a clinically meaningful limitation, while an increase toward normal values over time was interpreted as a positive treatment response. Each movement was measured three times, and the mean value was used for analysis. ROM assessments were performed at baseline and after each intervention period.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Upper Extremity Function
大体时间:The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Upper-extremity functioning was assessed using the Disabilities of the Arm, Shoulder and Hand (QuickDASH) Functioning Scale, a self-reported questionnaire designed to evaluate physical function and symptoms related to upper-limb disorders. The QuickDASH consists of 30 items, each scored on a 5-point Likert scale ranging from 1 (no difficulty) to 5 (unable to perform or extreme difficulty).

Item scores are combined and transformed into a total score ranging from 0 to 100, where 0 indicates no disability and 100 represents the most severe functional limitation. Higher scores therefore reflect worse upper-extremity functioning and greater disability.

A decrease in QuickDASH score over time indicates functional improvement, whereas an increase reflects worsening functional status. The QuickDASH has no absolute clinical cut-off; however, changes of 10-15 points are generally considered clinically meaningful.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Grip Strength
大体时间:The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Grip strength was assessed using a Jamar hand dynamometer, a widely accepted and reliable instrument for measuring isometric hand grip strength in clinical and research settings. Measurements were recorded in kilograms (kg), with higher values indicating greater muscle strength and better functional capacity, and lower values reflecting reduced grip strength.

Participants were seated in a standardized position with the shoulder adducted and neutrally rotated, the elbow flexed at 90 degrees, the forearm in a neutral position, and the wrist positioned between 0-30° extension and 0-15° ulnar deviation. Participants were instructed to squeeze the dynamometer with maximal effort for a few seconds. Each hand was tested three times, with adequate rest between trials to minimize fatigue, and the mean value was used for analysis.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Seda Yildiz, PhD、Halic University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年2月8日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2027年4月1日

研究注册日期

首次提交

2026年2月23日

首先提交符合 QC 标准的

2026年11月2日

首次发布 (实际的)

2026年11月5日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年2月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All data obtained from the assessment scales used in the study will be shared; however, patients' personal information, including names, surnames, and contact details, will be kept confidential. These personal data will only be shared on an individual basis if specifically requested.

IPD 共享支持信息类型

  • 研究方案
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅